Early risk check for thyroid eye disease in new Graves' disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study looks at people newly diagnosed with Graves' disease to see who might develop thyroid eye disease, a condition that can affect the eyes. It aims to find early signs so that treatment can be started sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been recently diagnosed with Graves' disease.
- Your blood tests show high thyroid hormone levels and a positive TSH receptor antibody test (TRAb > 1.5 IU/L).
- You live in or are treated in the Capital Region of Denmark (including certain hospitals).
- You can give informed consent to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
This study uses MRI scans of the eye area to better understand and classify thyroid eye disease (TED). It aims to help doctors predict outcomes and personalize treatment. You may be eligible if you have stable TED or are a healthy volunteer.
This trial tests a new medicine called MHB018A for people with active thyroid eye disease (TED), a condition that causes the eyes to bulge and become inflamed. The study aims to see if the drug can reduce symptoms and improve eye appearance compared to a placebo.
This study tests an investigational medication for thyroid eye disease, which causes bulging eyes and discomfort. The treatment is given as an injection near the eye, and the study will last about 12 months to see how safe and effective it is.
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
This trial tests an investigational drug called YB-101 for people with Graves' disease, whether or not they have thyroid eye disease. The goal is to see if the drug is safe and can help.
Hear when a new Graves Orbitopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.